SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Montana Wildhack who wrote (1875)5/14/1999 7:01:00 AM
From: Mark Bartlett  Read Replies (3) of 14101
 
Wolf,

<<Do you know what the differences in the process would be?>>

Not the specifics - I do know that when a drug is approved, and a company is seeking new indications or minor changes, there is usually no need to repeat a lot of the safety studies, since they were already done once.

Because I suspect the DMX carrier (for the most part) would be combined with other drugs that have also already been approved, my sense is they would only need to prove efficacy for any new agents.

I have a few contacts in the pharma biz ..... I'll be speaking to one next week. I'll see if she can give me more specifics. Perhaps Joseph can give more details.

MB

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News